CareDx (NASDAQ:CDNA – Get Free Report) and CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.
Earnings and Valuation
This table compares CareDx and CytomX Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CareDx | $379.80 million | 10.30 | -$21.35 million | $2.39 | 31.15 |
| CytomX Therapeutics | $76.20 million | 5.38 | -$17.37 million | ($0.50) | -3.76 |
Insider and Institutional Ownership
67.8% of CytomX Therapeutics shares are owned by institutional investors. 2.4% of CareDx shares are owned by insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations and price targets for CareDx and CytomX Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CareDx | 0 | 4 | 4 | 1 | 2.67 |
| CytomX Therapeutics | 1 | 1 | 9 | 1 | 2.83 |
CareDx currently has a consensus price target of $70.33, indicating a potential downside of 5.52%. CytomX Therapeutics has a consensus price target of $12.10, indicating a potential upside of 543.62%. Given CytomX Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than CareDx.
Risk & Volatility
CareDx has a beta of 2.51, suggesting that its share price is 151% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500.
Profitability
This table compares CareDx and CytomX Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CareDx | 25.86% | 9.74% | 7.35% |
| CytomX Therapeutics | -608.98% | -33.97% | -27.19% |
Summary
CareDx beats CytomX Therapeutics on 7 of the 13 factors compared between the two stocks.
About CareDx
CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Founded in 2008 and headquartered in South San Francisco, California, the company researches therapies designed to target tumors while limiting activity in healthy tissues. Its Probody platform uses molecular masks intended to keep therapeutic antibodies inactive until they encounter enzymes associated with the tumor environment. CytomX applies this approach to investigational medicines, including antibody-drug conjugates and immune-cell-engaging therapies.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
